Detalhe da pesquisa
1.
Natural history, response to systemic therapy, and genomic landscape of plasmacytoid urothelial carcinoma.
Br J Cancer
; 124(7): 1214-1221, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33473164
2.
A phase 2 trial of buparlisib in patients with platinum-resistant metastatic urothelial carcinoma.
Cancer
; 126(20): 4532-4544, 2020 10 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32767682
3.
Correction: Natural history, response to systemic therapy, and genomic landscape of plasmacytoid urothelial carcinoma.
Br J Cancer
; 126(8): 1236, 2022 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-35145255
4.
Evaluating the association of multiple single nucleotide polymorphisms with response to gemcitabine and platinum combination chemotherapy in urothelial carcinoma of the bladderâ©.
Int J Clin Pharmacol Ther
; 55(3): 203-209, 2017 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-28177276
5.
The high incidence of vascular thromboembolic events in patients with metastatic or unresectable urothelial cancer treated with platinum chemotherapy agents.
Cancer
; 122(5): 712-21, 2016 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26618338
6.
The safety and efficacy of single-agent pemetrexed in platinum-resistant advanced urothelial carcinoma: a large single-institution experience.
Oncologist
; 20(5): 508-15, 2015 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-25845990
7.
Phase II study of everolimus in metastatic urothelial cancer.
BJU Int
; 112(4): 462-70, 2013 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-23551593
8.
Novel Genetic Subtypes of Urothelial Carcinoma With Differential Outcomes on Immune Checkpoint Blockade.
J Clin Oncol
; 41(17): 3225-3235, 2023 06 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36927002
9.
Clinical and Genomic Landscape of FGFR3-Altered Urothelial Carcinoma and Treatment Outcomes with Erdafitinib: A Real-World Experience.
Clin Cancer Res
; 29(22): 4586-4595, 2023 11 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-37682528
10.
Neoantigen-specific CD8 T cell responses in the peripheral blood following PD-L1 blockade might predict therapy outcome in metastatic urothelial carcinoma.
Nat Commun
; 13(1): 1935, 2022 04 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35410325
11.
Long-term Outcomes of Local and Metastatic Small Cell Carcinoma of the Urinary Bladder and Genomic Analysis of Patients Treated With Neoadjuvant Chemotherapy.
Clin Genitourin Cancer
; 20(5): 431-441, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35676169
12.
Clinical and Genomic Characterization of Bladder Carcinomas With Glandular Phenotype.
JCO Precis Oncol
; 6: e2100392, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35731998
13.
Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial.
J Clin Oncol
; 40(12): 1312-1322, 2022 04 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-35089812
14.
The Cost of Enfortumab Vedotin Wastage Due to Vial Size-A Real-World Analysis.
Cancers (Basel)
; 13(23)2021 Nov 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-34885086
15.
Genitourinary Medical Oncology Expert Opinion Survey Regarding Treatment Management in the COVID-19 Pandemic.
Clin Genitourin Cancer
; 19(3): e178-e183, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33579638
16.
A phase II trial of durvalumab and tremelimumab in metastatic, non-urothelial carcinoma of the urinary tract.
Cancer Med
; 10(3): 1074-1083, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33382520
17.
Neoadjuvant Gemcitabine-Cisplatin Plus Radical Cystectomy-Pelvic Lymph Node Dissection for Muscle-invasive Bladder Cancer: A 12-year Experience.
Clin Genitourin Cancer
; 18(5): 387-394, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32273235
18.
Cancer Susceptibility Mutations in Patients With Urothelial Malignancies.
J Clin Oncol
; 38(5): 406-414, 2020 02 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31794323
19.
Nomogram to Assess the Survival Benefit of New Salvage Agents for Metastatic Urothelial Carcinoma in the Era of Immunotherapy.
Clin Genitourin Cancer
; 16(4): e961-e967, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29706503
20.
Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers.
J Clin Oncol
; 36(17): 1685-1694, 2018 06 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-29489427